Antiplatelet Agents

Antiplatelet agents inhibit platelet activation and aggregation, the primary-haemostasis processes that drive arterial thrombosis. The main classes act at different points of the platelet activation pathway: aspirin irreversibly blocks thromboxane synthesis, the P2Y12 inhibitors block ADP-mediated amplification, and the glycoprotein IIb/IIIa inhibitors block the final common step of fibrinogen-mediated aggregation. They are the cornerstone of treatment and prevention for atherothrombotic arterial disease.

Definition

Antiplatelet agents are drugs that suppress platelet activation and aggregation by inhibiting thromboxane A2 synthesis, the platelet ADP (P2Y12) receptor, or the glycoprotein IIb/IIIa integrin, thereby reducing platelet-driven (arterial) thrombus formation.

Scope

This entry covers the platelet activation pathway as a drug target, the principal antiplatelet classes and their mechanisms, and the concept of dual antiplatelet therapy combining aspirin with a P2Y12 inhibitor. It is a reference description of the drug class and not dosing or treatment guidance.

Core questions

• How do platelets become activated, and which steps of that pathway do antiplatelet drugs target?
• How does aspirin's irreversible inhibition of cyclooxygenase differ from reversible antiplatelet mechanisms?
• What distinguishes the P2Y12 inhibitors from one another in reversibility and metabolism?
• Why are aspirin and a P2Y12 inhibitor often combined as dual antiplatelet therapy in arterial disease?

Key concepts

• Platelet adhesion, activation, and aggregation
• Thromboxane A2 and cyclooxygenase-1 inhibition
• Irreversible (aspirin) versus reversible inhibition
• P2Y12 (ADP) receptor antagonism
• Glycoprotein IIb/IIIa integrin and final common pathway
• Dual antiplatelet therapy
• Atherothrombosis and platelet-rich arterial thrombi

Mechanisms

Platelets adhere to exposed subendothelium, become activated, and aggregate through fibrinogen bridges between glycoprotein IIb/IIIa receptors; activation is amplified by released mediators including thromboxane A2 and ADP. Davi and Patrono describe how this process underlies atherothrombosis. Aspirin irreversibly acetylates cyclooxygenase-1, abolishing platelet thromboxane A2 production for the life of the platelet, which Patrono and colleagues set out as the basis for low-dose aspirin. The P2Y12 inhibitors block the ADP receptor that amplifies activation: clopidogrel and prasugrel are thienopyridine prodrugs that bind irreversibly, while ticagrelor binds reversibly and does not require metabolic activation. Glycoprotein IIb/IIIa inhibitors block the final common integrin step of aggregation. Because these mechanisms are partly complementary, aspirin and a P2Y12 inhibitor are often combined as dual antiplatelet therapy.

Clinical relevance

Antiplatelet agents are central to the prevention and treatment of atherothrombotic events such as acute coronary syndromes and ischaemic stroke, and their use is summarised in the ACCP antiplatelet guidance. This entry explains how the class works and how its members differ; it is reference education and not a basis for dosing or individual treatment decisions.

Epidemiology

Aspirin and the P2Y12 inhibitors are among the most widely used cardiovascular drugs. As with anticoagulants, bleeding is the principal adverse effect, and the balance of ischaemic benefit against bleeding harm, particularly with dual antiplatelet therapy, is a recurring theme in the trial and guideline literature.

History

Aspirin's antiplatelet action through cyclooxygenase inhibition was elucidated in the early 1970s, establishing the first widely used antiplatelet agent. The thienopyridines, ticlopidine and then clopidogrel, introduced P2Y12 receptor blockade, and glycoprotein IIb/IIIa inhibitors followed for acute settings. Newer P2Y12 inhibitors such as prasugrel and the reversible, non-prodrug ticagrelor, evaluated against clopidogrel in trials including the work of Wallentin and colleagues, expanded the class in acute coronary syndromes.

Debates

How should the benefit of intensified antiplatelet therapy be balanced against bleeding?

More potent or combined antiplatelet regimens reduce ischaemic events but increase bleeding, and how to weigh this trade-off, including the choice and duration of dual antiplatelet therapy, is a continuing focus of the trial and guideline literature.

Key figures

• Carlo Patrono
• Giovanni Davi
• Lars Wallentin
• John Eikelboom

Seminal works

• patrono-2005
• davi-2007
• wallentin-2009

Frequently asked questions

How is an antiplatelet agent different from an anticoagulant?

Antiplatelet agents inhibit platelet activation and aggregation, the primary-haemostasis step that drives platelet-rich arterial thrombi, whereas anticoagulants act on the coagulation cascade and fibrin formation. The two classes target different arms of haemostasis.

Why is aspirin's antiplatelet effect long-lasting at low doses?

Aspirin irreversibly inactivates cyclooxygenase-1 in the platelet, and because platelets cannot synthesise new enzyme, the loss of thromboxane production persists for the platelet's lifespan until new platelets are formed.